EP4 receptor selective agonist in the treatment of osteoporosis

Details EP4 receptor selective agonist in the treatment of osteoporosis EP4 receptor selective agonist in the treatment of osteoporosis

2007-03-20

2007-03-20

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S204000, C548S541000, C548S551000, C514S422000

Reexamination Certificate

active

10668633

ABSTRACT:
This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I,wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.

REFERENCES:
patent: 3975399 (1976-08-01), DeFranco et al.
patent: 4113873 (1978-09-01), Himizu et al.
patent: 4115401 (1978-09-01), Nanthavong et al.
patent: 4177346 (1979-12-01), Nelson
patent: 4320136 (1982-03-01), Scribner
patent: 4456613 (1984-06-01), Wang
patent: 5594014 (1997-01-01), Macor et al.
patent: 5712299 (1998-01-01), Boar et al.
patent: 5955481 (1999-09-01), Ohara et al.
patent: 6552067 (2003-04-01), Cameron et al.
patent: 6573294 (2003-06-01), Old et al.
patent: 6610719 (2003-08-01), Paralkar et al.
patent: 6747054 (2004-06-01), Cameron et al.
patent: 2618341 (1976-11-01), None
patent: 2619638 (1977-11-01), None
patent: 0046082 (1985-06-01), None
patent: 1121939 (2001-08-01), None
patent: 1132086 (2001-09-01), None
patent: 1110949 (2003-09-01), None
patent: 1158163 (1969-07-01), None
patent: 1343014 (1974-01-01), None
patent: 1487842 (1977-10-01), None
patent: 1553595 (1979-10-01), None
patent: 1583163 (1981-01-01), None
patent: 2124012 (1998-12-01), None
patent: 2125053 (1999-01-01), None
patent: 2139863 (1999-10-01), None
patent: WO0021532 (2000-04-01), None
patent: WO0021542 (2000-04-01), None
Nelson et al (1980): STN International CAPLUS database, Columbus (Ohio), Accession No. 1980: 146340.
Translated Claims of DE2618341.
Baraldi, et al., “Azaprostaglandins. Synthesis and Anticulcer Activity of 11-Deoxy-8-Azaprostaglandin Analogues”,II Farmaco—Ed. Sc.38(7), pp. 498-507.

Affiliated with

Also associated with

Rating

EP4 receptor selective agonist in the treatment of osteoporosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EP4 receptor selective agonist in the treatment of osteoporosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP4 receptor selective agonist in the treatment of osteoporosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3770997